Insider Selling: Phreesia, Inc. (NYSE:PHR) CFO Sells $20,571.84 in Stock

Phreesia, Inc. (NYSE:PHR) CFO Balaji Gandhi sold 864 shares of the company’s stock in a transaction dated Wednesday, April 16th. The shares were sold at an average price of $23.81, for a total transaction of $20,571.84. Following the completion of the transaction, the chief financial officer now owns 107,547 shares in the company, valued at approximately $2,560,694.07. This trade represents a 0.80 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Balaji Gandhi also recently made the following trade(s):

• On Tuesday, April 8th, Balaji Gandhi sold 8,045 shares of Phreesia stock. The stock was sold at an average price of $23.85, for a total value of $191,873.25.
• On Wednesday, March 26th, Balaji Gandhi sold 1,827 shares of Phreesia stock. The stock was sold at an average price of $27.46, for a total value of $50,169.42.
• On Tuesday, February 18th, Balaji Gandhi sold 5,771 shares of Phreesia stock. The stock was sold at an average price of $30.04, for a total value of $173,360.84.
• On Thursday, February 13th, Balaji Gandhi sold 28,759 shares of Phreesia stock. The shares were sold at an average price of $30.00, for a total transaction of $862,770.00.
• On Monday, January 27th, Balaji Gandhi sold 4,813 shares of Phreesia stock. The stock was sold at an average price of $27.48, for a total transaction of $132,261.24.
• On Tuesday, January 21st, Balaji Gandhi sold 5,827 shares of Phreesia stock. The shares were sold at an average price of $27.31, for a total value of $159,135.37.

Phreesia Price Performance

PHR stock opened at $23.92 on Friday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.74 and a current ratio of 1.74. Phreesia, Inc. has a 52-week low of $17.07 and a 52-week high of $30.53. The company has a market capitalization of $1.41 billion, a P/E ratio of -16.27 and a beta of 0.82. The company has a fifty day moving average price of $26.07 and a 200-day moving average price of $24.31.

Institutional Investors Weigh In On Phreesia

Institutional investors have recently made changes to their positions in the stock. State Street Corp lifted its stake in shares of Phreesia by 7.1% in the third quarter. State Street Corp now owns 1,327,586 shares of the company’s stock worth $30,256,000 after acquiring an additional 88,517 shares during the period. XTX Topco Ltd bought a new position in Phreesia during the 3rd quarter worth approximately $247,000. Barclays PLC lifted its holdings in Phreesia by 83.6% in the third quarter. Barclays PLC now owns 94,929 shares of the company’s stock valued at $2,163,000 after buying an additional 43,225 shares during the period. Geode Capital Management LLC boosted its position in Phreesia by 4.7% during the third quarter. Geode Capital Management LLC now owns 1,245,797 shares of the company’s stock valued at $28,397,000 after acquiring an additional 55,934 shares during the last quarter. Finally, Franklin Resources Inc. grew its holdings in Phreesia by 3.0% during the 3rd quarter. Franklin Resources Inc. now owns 1,497,631 shares of the company’s stock worth $31,495,000 after acquiring an additional 42,973 shares during the period. Institutional investors own 92.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on PHR. Royal Bank of Canada upgraded Phreesia from a “sector perform” rating to an “outperform” rating and raised their price target for the stock from $24.00 to $32.00 in a research report on Wednesday, January 8th. Canaccord Genuity Group increased their price target on shares of Phreesia from $34.00 to $35.00 and gave the stock a “buy” rating in a research report on Thursday, March 13th. DA Davidson cut their target price on Phreesia from $36.00 to $34.00 and set a “buy” rating for the company in a research note on Monday, April 14th. Needham & Company LLC reiterated a “buy” rating and issued a $29.00 price target on shares of Phreesia in a research note on Thursday, March 13th. Finally, KeyCorp dropped their price objective on Phreesia from $30.00 to $28.00 and set an “overweight” rating for the company in a research report on Wednesday. Twelve research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Phreesia currently has an average rating of “Buy” and an average price target of $31.33.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.